Table 2. Summary of patients with neurological disorders and COVID-19.
NA = Not available, SD = Standard Deviation
| Author (Reference) | Study Design | Age (mean ± SD) | Male (%) | Total Number of patients with neurological disorders | Types of neurological disorder | Key exacerbating symptoms or severe symptoms | Number of patients with preexisting neurological disorders having severe COVID symptoms | Death or Mortality rate (%) |
| Asadi‐Pooya et al. [8] | Case control study | 52±23 | 53.2 | 1086 | Epilepsy, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, Multiple sclerosis, Unspecified | Seizure | NA | Case fatality rate 8.5% |
| Brown et al. [9] | Cross sectional study | 65 | 73% | 5429 | Parkinson's disease | Motor and Non-motor symptoms (mood, cognition, sleep, autonomic) | NA | NA |
| Drabik et al. [10] | Cohort study | 64 | 45.28 | 349 | Stroke, Dementia, Parkinson's disease, Epilepsy, CNS tumor, Traumatic brain injury | Headache, dizziness, dementia, decreased consciousness, stroke, seizure, ataxia | NA | 9.46 |
| El‐Qushayri et al. [11] | Systematic review and meta-analysis | NA | NA | 8649 | Parkinson's disease | NA | Poor in-hospital outcomes of COVID-19 [OR 2.64 (95% CI 1.75–3.99), p < 0.00001 | 25.10% |
| Eskandar et al. [12] | Case control study | 65 | NA | 581 | Stroke, Seizure | Altered mentation, Stroke, Seizure, Neuro covid 19 complexes | NA | 58.70% |
| Fan et al. [13] | Cross sectional study | NA | NA | (1836+3060)=4864 | Multiple Sclerosis, Neuromyelitis Optica Spectrum disorders | NA | 2 | NA |
| Flores-Silva, et al. [14] | Cross sectional study | 53.2 ±13.7 | 65 | 163 | Epilepsy, Ischemic stroke, Multiple sclerosis, and Parkinson’s disease | Seizure, Stroke, Delirium, Myopathy, Headache | NA | 19.60% |
| Garjani et al. [15] | Prospective cohort study | 49 (<4wks) 50 (≥4wks) 51 (>12 wks.) | 25.9 (<4wks) 17.6 (≥4wks)15.5 (>12wks) | 7977 | Multiple sclerosis | Change in smell or taste, headache, fever, New muscle pain ,and New or worse fatigue, Upper respiratory tract, lower respiratory tract and Gastrointestinal tract symptoms | 1096 | NA |
| Harb et al. [16] | Cohort study | 84 (for patients with dementia) | 43.1 | 116 | Dementia | Delirium, Dyspnea | 50/116 (developed ARDS) | 50 |
| Hu et al. [17] | Cohort study | 74.2 ±5.84 | 53 | 2617 | Neurodegenerative disease | NA | 379 | 7.5 |
| Huber et al. [18] | Prospective cohort study | Median decade 76-85years | 59 | 330 | Parkinson’s disease, Dementia | Dry cough, Dyspnea, Fever, Delirium, Headache, Taste disorder | NA | 32.5 (Parkinson's disease) 32.1 (Dementia) |
| Kubota et al. [19] | Systematic review | NA | NA | 232 | Dementia, Parkinson’s disease, Epilepsy, and Unspecified neurological disorders | Dementia, Parkinson’s disease, Multiple sclerosis, Epilepsy | 478 | NA |
| Kuroda et al. [20] | Review article | NA | NA | NA | Epilepsy | Seizure | NA | NA |
| Louapre et al. [21] | Cohort study | 44.6±12.8 | 28.2 | 347 | Multiple sclerosis | ARDS | 73 | 3.46 |
| Nejad et al. [22] | Cross-sectional study | Different age group was compared | 57.2 | 891 | Stroke, Seizure | Headache, sleeping problem, anosmia, dizziness, hypogeusia, memory issues, seizure | NA | NA |
| Numbers and Brodaty [23] | Review article | NA | NA | NA | Alzheimer’s disease, Dementia | Severe virus related outcome including death | NA | Mortality increased |
| Parrotta et al. [24] | Cross-sectional | 44.9 ± 15.2 | 38.2 | 72 | Multiple sclerosis | Relapsing of neurological symptoms | 8 | 8.33 |
| Santos‐García et al. [25] | Cross- sectional study | 63.5±12.5 | 47 | NA | Parkinson's disease | Tremor, rigidity, fluctuation of motor symptoms, etc. | NA | NA |
| Yassin et al. [26] | Systematic review and meta analysis | 50.3 | 53 | NA | NA | Myalgia, taste impairment, smell impairment, headache, dizziness, encephalopathy, CVD. | NA | NA |
| Zhang et al. [27] | Case series | 70( for stroke patients) | 67 | 49 | Stroke | Sepsis, ARDS, Acute kidney injury | NA | 45 |